The Institute for Clinical and Economic Review (ICER) on Thursday, May 2, suggested in a recently-released evidence report that Novartis' siponimod, which is used in the treatment of secondary progressive multiple sclerosis (SPMS), "far exceeds" common quality-adjusted life year and life year gained […]
Recent ICON Paper Points to Higher-Than Expected Impact of ICER Assessments
A recent paper by ICON suggests the Institute for Clinical and Economic Review's (ICER) drug assessments carry more weight in decision-making among payers than originally expected, according to an article published on Forbes. The white paper, titled "Industry Perceptions and Expectations: The Role […]
ICER Posts Draft Scoping Document for RA Treatments
The Institute for Clinical and Economic Review (ICER) on Thursday, April 11, released a draft scoping document for a planned review of treatments for rheumatoid arthritis (RA). According to a press release, ICER's assessment will include new data on RA treatments since its 2017 review. "In […]
ICER Plans Assessment of Type 2 Diabetes Treatments
The Institute for Clinical and Economic Review (ICER) announced Thursday, April 11, that it will review the comparative clinical effectiveness and value of several treatments for type 2 diabetes. According to a press release, ICER will assess Novo Nordisk's oral semaglutide and compare it to Novo […]
ICER Releases Report on Peanut Allergy Treatments
The Institute for Clinical and Economic Review on Tuesday, April 9, released a draft evidence report on the clinical effectiveness and value of DBV Technologies' Viaskin Peanut and Aimmune Therapeutics' AR101 for inducing immune tolerance to peanuts. The report will be open to public comment until […]
ICER Recommends Major Price Drop for Spinraza
The Institute for Clinical and Economic Review (ICER) announced the release of its final report on Spinraza and Zolgensma for treatment of spinal muscular atrophy, and in it recommended a major price reduction for Spinraza. No recommendation was made on Zolgensma's price since its treatment price […]
ICER Names New CSO
The Institute for Clinical and Economic Review (ICER) on Tuesday, April 2, announced Pamela Bradt would serve as the organization's chief science officer. According to a press release, Bradt will lead research initiatives and play a key role in helping "evolve ICER's methods of value assessment and […]
Analysis: ICER Framework in Medicaid Could Threaten 820K Prescriptions
If Medicaid used the Institute for Clinical and Economic Review's (ICER) value framework, some 42-99 percent of prescriptions for serious conditions would be at risk of not being covered, a new analysis from Xcenda suggests. PhRMA in a blog post says those figures reveal "the dangerous effects […]
ICER Releases Draft Report on Esketamine
The Institute for Clinical and Economic Review (ICER) on Thursday, March 21, posted a draft evidence report on Janssen's esketamine for treatment-resistant depression. An open input period on the report remains open until 5 p.m. EST April 17. The evidence report is slated to be released May 9, and […]
ICER Names New Members to Independent Appraisal Councils
The Institute for Clinical and Economic Review (ICER) announced on Monday, March 18, that it had appointed new members to its three independent evidence appraisal councils. The three councils are the California Technology Assessment Forum, the Midwest Comparative Effectiveness Public Advisory […]
